Suven Life Sciences Limited · NSE:SUVEN
Suven Life Sciences — Q3 FY2018-19 Earnings Presentation
14 slides from Suven Life Sciences's earnings presentation, Feb 5, 2019
Slide 1: SUVEN Life Sciences Ltd - Communication to investors
SUVEN Life Sciences Ltd Communication to investors December 2018 5-Feb-19 2018-19 Q3 results
Slide 2: Risk statement
Risk statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in m
Slide 3: Financial Quick View
FINANCIAL QUICK VIEW FY 2018-19 FY 2018-19 Q3 to Q2 YoY 9 months Growth in revenue 40.24% 1.20% Growth in Pre-R&D EBIDTA 27.66% -8.18% Growth in EBIDTA 33.41% -10.92% Growth in PAT 40.27% -14.57% R&D to sales 10.41% 9.85% Increase in R&D Costs 13.27% 2.06% 5-Feb-19 2018-19 Q3 results
Slide 4: Major Profitability Ratios
MAJOR PROFITABILITY RATIOS Q3 Dec 18 9 months- Dec 18 Pre-R&D EBITDA 41.10% 42.06% to Income EBIDTA to 30.69% 32.21% Income PAT to Income 18.67% 19.01% Cash Flow to 22.83% 22.88% Income 5-Feb-19 2018-19 Q3 results
Slide 5: Q3 to Q2 Comparison
Q3 to Q2 COMPARISON Current quarter to previous quarter Revenue - INR Million PAT - INR Million 1,600.00 1,347.83 300.00 251.65 250.00 1,100.00 961.08 200.00 179.41 600.00 150.00 100.00 100.00 Q2 Sep 18 Q3 Dec 18 Q2 Sep 18 Q3 Dec 18 EBIDTA - INR Million Pre-R&D EBIDTA - INR Million 450.00 413.59 650
Slide 6: Revenue Comparison
REVENUE COMPARISON Year on year INR Million 5,000.00 4,500.00 4,255.80 4,306.81 4,000.00 3,500.00 3,000.00 2,500.00 2,000.00 1,669.47 1,500.00 1,347.83 1,000.00 500.00 - Q3 Dec 17 Q3 Dec 18 9M Dec 17 9M Dec 18 5-Feb-19 2018-19 Q3 results
Slide 7: PAT Comparison
PAT COMPARISON Year on year INR Million 1,200.00 1,000.00 958.43 818.78 800.00 600.00 400.00 345.74 251.65 200.00 - Q3 Dec 17 Q3 Dec 18 9M Dec 17 9M Dec 18 5-Feb-19 2018-19 Q3 results
Slide 8: EBIDTA Comparison
EBIDTA COMPARISON Year on year INR Million 1,800.00 1,600.00 1,557.19 1,387.19 1,400.00 1,200.00 1,000.00 800.00 600.00 546.81 413.59 400.00 200.00 - Q3 Dec 17 Q3 Dec 18 9M Dec 17 9M Dec 18 5-Feb-19 2018-19 Q3 results
Slide 9: R & D – Expenditure
R & D – EXPENDITURE Year on year INR Million 450.00 424.07 415.52 400.00 350.00 300.00 250.00 200.00 150.00 138.78 140.31 100.00 50.00 - Q3 Dec 17 Q3 Dec 18 9M Dec 17 9M Dec 18 5-Feb-19 2018-19 Q3 results
Slide 10: Pre-R&D EBIDTA
PRE-R&D EBIDTA Year on year INR Million 2,500.00 1,972.70 2,000.00 1,811.26 1,500.00 1,000.00 685.59 553.90 500.00 - Q3 Dec 17 Q3 Dec 18 9M Dec 17 9M Dec 18 5-Feb-19 2018-19 Q3 results
Slide 11: Pre-R&D Cashflow
PRE-R&D CASHFLOW Year on year INR Million 1,800.00 1,600.00 1,533.43 1,409.63 1,400.00 1,200.00 1,000.00 800.00 600.00 538.69 448.05 400.00 200.00 - Q3 Dec 17 Q3 Dec 18 9M Dec 17 9M Dec 18 5-Feb-19 2018-19 Q3 results
Slide 12: Financial Snapshot
FINANCIAL SNAPSHOT All figures are in INR Million, other than ratios and EPS 2018-19 2018-19 Growth 2017-18 Growth 2018-19 2017-18 Growth Q3 Q2 % Q3 % 9 mons 9 mons % Income 1,347.83 961.08 40.24% 1,669.47 -19.27% 4,306.81 4,255.80 1.20% Pre-R&D EBITDA 553.90 433.88 27.66% 685.59 -19.21% 1,811.26 1,
Slide 13: News Release
News Release • During the period Suven secures 4 product patents covering Brasil, Eurasia, Australia and Singapore • Suven presented in B&K Investor Conference - Emergent India in December 2018 • The Board has proposed an Interim Dividend of Re. 1.50 per share (150% of face value of Rs. 1.00 each) 5
Slide 14: News Release
News Release • Suven Board approved of demerger of Contract Research and Manufacturing Services (CRAMS) undertaking of Suven Life Sciences Limited (SLSL) into Suven Pharmaceuticals Limited (SPL), through a scheme of arrangement, subject to approval of respective regulatory authorities. More details
Suven Life Sciences — Q3 FY2018-19 Earnings Presentation on 6ix